Furthermore, following 24-hour treatment with trametinib + dabrafenib, the MEK and BRAF inhibitors that are the standard-of-care treatment for melanoma (34), A375s increase their expression of Axl while decreasing their shedding of the receptor (Figure 1C). This evidence concerns the gene MAP2K7 and melanoma.